You are here

What’s the Stem Cells Buzz this Week? - Enhancing iPSC-EC Function, Regulating SMC Differentiation, Improving Gene Editing in HSCs, and Promoting BM-MSC Osteogenesis!

Comment

Discuss

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Endothelial Cell‐specific Molecule 1 Enhances the Function of iPSC-derived Endothelial Cells

New research from the lab of Andriana Margariti (Queen's University Belfast, UK) recently sought to understand the transcriptional regulation of endothelial cells generated from patient-derived human induced pluripotent stem cells (hiPSCs) to aid the treatment of vascular disease. In their new report, Vilà‐González et al. establish the relative importance of Endothelial cell‐specific molecule 1 (ESM1) signaling in improving the function and neovascularization potential in endothelial cells generated from iPSCs in vitro and in vivo. Discover more of the details at STEM CELLS now.

Glycoprotein M6B Regulates Smooth Muscle Cell Differentiation

Smooth muscle cells (SMCs) play a vital role in vascular development and the pathogenic process of vascular remodeling, although the molecular mechanisms governing their differentiation remain poorly understood. Now, researchers led by Ling Tao and Shan Wang (Fourth Military Medical University, Xi'an, Shaanxi, China) have demonstrated that glycoprotein M6B (GPM6B) regulates SMC differentiation through the activation of TGF-β-Smad2/3 signaling via direct interactions with TβRI. Zhang et al. anticipate that GPM6B will represent a potentially attractive target for the regulation of SMC differentiation and cardio-vascular regenerative medicine. See STEM CELLS now to discover more.

Improving Gene Editing Outcomes in Human Hematopoietic Stem Cells

The wide-ranging clinical application of CRISPR/Cas9‐mediated gene edited human hematopoietic stem cells (HSCs) as a treatment of genetic blood diseases requires the development of the technology to increase the precision of genetic modification. A STEM CELLS study led by Donald B. Kohn (University of California Los Angeles, Los Angeles, California, USA) now reports that a modified version of Cas9 with reduced nuclease activity in G1 phase of cell cycle combined with a transient increase in the proportion of cells in homology-directed repair (HDR)‐preferred phases (S/G2) leads to increased precision. Furthermore, Lomova et al. demonstrate that edited HSCs display a significant improvement after xenotransplantation into immune‐deficient mice, thereby encouraging the application of CRISPR/Cas9-modified HSCs in the treatment of congenital diseases of the blood system.

LncRNA-OG Promotes Bone Marrow-derived Mesenchymal Stem Cell Osteogenesis

Previous studies from Huiyong Shen and Yanfeng Wu (Sun Yat‐sen University, Guangzhou, Guangdong, China) analyzed long noncoding RNA (lncRNA) expression profiles in during the osteogenesis of bone marrow‐derived mesenchymal stem cells (BM‐MSCs). Now, Tang et al. report in a STEM CELLS study that a novel positive functional osteogenesis-associated lncRNA, lncRNA-OG, regulates the activation of BMP signaling pathway by interacting with the major pre-mRNA-binding protein heterogeneous nuclear ribonucleoprotein K (hnRNPK), which positively regulates lncRNA-OG transcriptional activity. The authors hope that their findings will boost the clinical application of BM-MSC in osteogenic applications.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!